Skip to main content
SpringerLink
Log in

Impatto della 18F-DOPA PET/CT nella gestione clinica del carcinoma midollare della tiroide

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

L’ecografia del collo è l’esame morfologico di immagine di primo livello per identificare la recidiva del carcinoma midollare della tiroide (CMT). In assenza di criteri ecografici dirimenti e in presenza di valori elevati di calcitonina può essere necessario introdurre una diagnostica per immagini di secondo livello in grado di esplorare con elevata sensibilità la regione cervicale e il corpo intero. Scopo principale di questo articolo è quello di riportare, nell’attuale contesto diagnostico, il ruolo della 18F-DOPA PET/CT (Total-Body) in caso di sospetta persistenza-recidiva di CMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Bibliografia

  1. Wells SA Jr, Asa SL, Dralle H et al. (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kauhanen S, Schalin-Jantti C, Seppanen M et al. (2011) Complementary roles of 18F-DOPA PET/CT and 18FFDG PET/CT in medullary thyroid cancer. J Nucl Med 52:1855–1863

    Article  CAS  PubMed  Google Scholar 

  3. Treglia G, Piccardo A, Giovanella L (2017) Radionuclide imaging of medullary thyroid carcinoma. In: Pacak K, Taïeb D (eds) Diagnostic and therapeutic nuclear medicine for neuroendocrine tumors. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319

    Chapter  Google Scholar 

  4. Skoura E, Datseris IE, Rondogianni P et al. (2012) Correlation between calcitonin levels and [18F]FDGPET/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer. ISRN Endocrinol 2012:375231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Treglia G, Villani MF, Giordano A, Ruffini V (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42:535–545

    Article  CAS  PubMed  Google Scholar 

  6. Taïeb D, Timmers HJ, Hindié E et al. the European Association of Nuclear Medicine (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1977–1979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Treglia G, Cocciolillo F, Di Nardo F et al. (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol 19:1290–1299

    Article  PubMed  Google Scholar 

  8. Luster M, Karges W, Zeich K et al. (2010) Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20(5):527–533

    Article  CAS  PubMed  Google Scholar 

  9. Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R et al. (2017) Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging 44:2004–2013

    Article  CAS  PubMed  Google Scholar 

  10. Verbeek HH, Plukker JT, Koopmans KP et al. (2012) Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 53:1863–1871

    Article  CAS  PubMed  Google Scholar 

  11. Werner RA, Schmid JS, Higuchi T et al. (2018) Predictive value of (18)F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med 59(5):756–761

    Article  CAS  PubMed  Google Scholar 

  12. Rasul S, Hartenbach S, Rebhan K et al. (2018) [(18)F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-4045-9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Nucleare, Ospedali Galliera di Genova, Genova, Italia

    Gianluca Bottoni, Michela Massollo & Arnoldo Piccardo

Authors
  1. Gianluca Bottoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michela Massollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnoldo Piccardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnoldo Piccardo.

Ethics declarations

Conflitto di interesse

Gli autori Gianluca Bottoni, Michela Massollo e Arnoldo Piccardo dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Alfredo Campennì.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 37 kB)

(DOC 37 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bottoni, G., Massollo, M. & Piccardo, A. Impatto della 18F-DOPA PET/CT nella gestione clinica del carcinoma midollare della tiroide. L'Endocrinologo 19, 307–311 (2018). https://doi.org/10.1007/s40619-018-00495-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-00495-9

Parole chiave

Search

Navigation